The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy
Open Access
- 29 June 2010
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 103 (2) , 201-208
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 31 references indexed in Scilit:
- Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222Journal of Clinical Oncology, 2009
- Biodistribution, pharmacokinetics and PET Imaging of [18F]FMISO, [18F]FDG and [18F]FAc in a sarcoma- and inflammation-bearing mouse modelNuclear Medicine and Biology, 2009
- Regulation of Oxygen Homeostasis by Hypoxia-Inducible Factor 1Physiology, 2009
- The tumor microenvironment and metastatic diseaseClinical & Experimental Metastasis, 2008
- Advantage of Combining NLCQ-1 (NSC 709257) with Radiation in Treatment of Human Head and Neck XenograftsRadiation Research, 2007
- Partial-Volume Effect in PET Tumor ImagingJournal of Nuclear Medicine, 2007
- Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefitMolecular Cancer Therapeutics, 2007
- Use of Three-Dimensional Tissue Cultures to Model Extravascular Transport and Predict In Vivo Activity of Hypoxia-Targeted Anticancer DrugsJNCI: Journal of the National Cancer Institute, 2006
- Tirapazamine Administered as a Neoadjuvant to Radiotherapy Reduces Metastatic DisseminationClinical Cancer Research, 2005
- Does local X-irradiation of a tumor increase the incidence of metastases?Cancer, 1981